An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new report from Stanford suggests that about one in ten people might not respond well to a common class of diabetes drugs called GLP-1 receptor agonists. These are the medicines behind widely known brand names used for type 2 diabetes and weight loss. The headline is short and attention-grabbing, but the underlying message is that a meaningful minority may get little benefit from these drugs. GLP-1 receptor agonists are medicines that copy a gut hormone called GLP-1 (glucagon-like peptide-1). In plain terms, they tell the body to release more insulin when blood sugar is high, slow how fast the stomach empties, and make you feel fuller. Semaglutide and liraglutide are examples. They don’t change DNA or permanently fix metabolism; they act while you take them and wear off after you stop. What Stanford’s team looked at is whether some people have what’s being called “resistance” to these drugs — meaning the medicines don’t produce the expected effects on blood sugar or weight. The headline “one in ten” comes from analysis suggesting roughly ten percent of people might show this low response. The report is not a large clinical trial proving the cause; it’s more a research finding indicating this pattern exists. The exact studies behind the number vary, and the reasons for resistance aren’t fully pinned down, so the effect size and who exactly falls into that ten percent remain somewhat uncertain. This matters because these drugs are now widely prescribed. If about one in ten people won’t get much benefit, patients and doctors need to know that early. For someone considering or starting a GLP-1 drug, it means watching outcomes closely — like blood sugar readings, weight change, and side effects — and being prepared to try different treatments if the medicine doesn’t help. Clinicians may also want to investigate why a person isn’t responding, which could point to other health issues or need for a different medication. There are important caveats. The idea of “resistance” here does not necessarily mean complete failure; it may mean a smaller-than-expected effect. The headline is an estimate, not a precise rule, and more research will be needed to confirm the exact rate and causes. GLP-1 drugs have known side effects like nausea and rarely more serious problems; they are prescription medicines and not appropriate for everyone. If you’re taking one or thinking about it, don’t stop or start based on headlines — talk with your clinician about what to expect, how you’ll measure benefit, and alternative options if needed. Bottom line: roughly one in ten people might get little benefit from GLP-1 diabetes drugs, so monitoring results and staying in close contact with your doctor is important.
Source: Stanford Medicine